Arnica Tincture
Phase 3Small molecule
Arnica Tincture is one of 11 small molecule programs targeting Cutaneous Leishmaniasis. It is currently in Phase 3.
1
Indications
2
Total Trials
2
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
15 competitors in Cutaneous Leishmaniasis
#DrugCompanyPhaseTrials
1Garamycin
SSchering-Plough
Approved
Abelcet
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Levaquin
WWim Janssens
Approved
Impavido
KKnight Therapeutics (USA) Inc
Phase 3
Trental
VValidus Pharmaceuticals
Phase 3
Flagyl
DDePuy Orthopaedics
Phase 2
Meglumine Antimoniate
UUniversity of Brasilia
Phase 3
Fusidic Acid
RochePhase 3
Arnica Tincture
UUniversidad de Antioquia
Phase 3
LXE408
NovartisPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Arnica Tincture. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- UUniversidad de Antioquia